Severe Asthma Clinical Trial
Official title:
A Randomized, Placebo Controlled, Double Blind Phase IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Multiple Intravenous Doses of FB704A in Adults With Severe Asthma
This is a randomized, placebo controlled and double blind study to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of FB704A in adult patients with severe asthma. The study comprised a 4-week screening period, a 8-week treatment period and a 12-week follow-up period.
Approximately 40 subjects who meet the criteria for study entry are planned to be enrolled to the study. Eligible subjects will be randomized to receive placebo or FB704A in a 1:1 ratio. There are 20 subjects participate in each arm. Eligibility will be checked in patients with severe asthma during the 4-week screening period. Potential candidates should provide signed informed consent forms before starting the screening activities. The subjects will receive four dose of 4 mg/kg FB704A or placebo. The study drug will be administered as a 1-hour IV infusion. Patients may administer Short-acting beta agonists (SABAs), such as albuterol as rescue medications as needed throughout the study. Subjects will have site visits after receiving study drug for efficacy, safety, PK, and biomarker evaluation (see Study Flow Chart). Subjects who prematurely withdraw from the study will have an end of study (EOS) visit within 7 days. Relative change in pre-bronchodilator FEV 1 , post-bronchodilator FEV 1, exhaled NO and asthma symptom s will be evaluated during the study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05472324 -
Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma.
|
Phase 2 | |
| Recruiting |
NCT04914078 -
Severe Asthma Exacerbations and Mepolizumab Treatment
|
||
| Completed |
NCT05576454 -
Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects
|
Phase 1 | |
| Recruiting |
NCT04438408 -
National Survey on Care Pathway and Quality of Life in Patients With Severe Asthma According to Their Phenotype.
|
||
| Recruiting |
NCT04520165 -
Effect of Biologicals on Alternative Functions of Eosinophils in Severe Asthma
|
||
| Not yet recruiting |
NCT04463836 -
Phenotyping Circulating and Lung Resident Eosinophils in Severe Asthma (P-CLESA)
|
||
| Recruiting |
NCT03377920 -
Predictive Value of Spirometric PIF to Produce PIF Rate Needed for the Use of Current DPI's.
|
N/A | |
| Recruiting |
NCT04565483 -
Predictive Signature of Benralizumab Response
|
Phase 4 | |
| Recruiting |
NCT04045587 -
International Severe Asthma Registry: Canadian Cohort
|
||
| Completed |
NCT05616338 -
Modeling Bronchial Epithelium in Severe Asthma With Human Induced Pluripotent Stem Cells (iPSC)
|
N/A | |
| Active, not recruiting |
NCT02038374 -
Clinico-biological Correlation of Severe Asthma in Children
|
N/A | |
| Active, not recruiting |
NCT02114034 -
Cohort Analysis of Clinical and Biological Severe Childhood Asthma
|
||
| Recruiting |
NCT06035289 -
Register Schweres Asthma - German Asthma Net e.V.
|
||
| Not yet recruiting |
NCT03532685 -
Clinical, Inflammatory and Functional Evaluation of a Population of Severe and Obese Asthmatics: Follow up
|
N/A | |
| Completed |
NCT03931954 -
Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients
|
||
| Recruiting |
NCT03984253 -
Swiss Severe Asthma Register
|
||
| Recruiting |
NCT03435237 -
Phenotyping Asthma for Bronchial Thermoplasty
|
||
| Recruiting |
NCT03476109 -
Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma.
|
Phase 4 | |
| Recruiting |
NCT04714567 -
Portuguese Severe Asthma Registry: Getting Answers for Severe Asthma Patients
|
||
| Recruiting |
NCT05164939 -
Precision Medicine Intervention in Severe Asthma (PRISM) Study
|